- Prev close
- $484.03
- Day range
- $482.10 – $497.39
- Next earnings
- in 86 days
VRTX fell -1.3% in a session where the S&P 500 rose 1.4% and the Nasdaq 100 rose 1.8%, while peers were also weaker; the move looks more like a sector-wide pause around a mixed Q2 print than stock-specific deterioration.
VRTX
VERTEX PHARMACEUTICALS INC
As of Aug 3, 2026
63/100
Worth keeping an eye onHealth ScoreWhy it moved
VRTX moved -1.3% even as the S&P 500 rose 1.4% and the Nasdaq 100 rose 1.3%, so the broad market does not explain it. Same-sector peers were also softer — ABBV -2.3% and AMGN -1.6% — with only GILD up 1.3%, which points to a sector-wide biotech/drug wobble rather than a company-specific break. The session also fits the recent mixed Q2 backdrop: Vertex reported 12% year-over-year revenue growth to $3.3 billion, but the quarter was described as mixed and the stock dipped despite raised guidance.
Normal volatility?
This looks like ordinary-to-moderate volatility for a high-quality biotech, not a deterioration event. The business still shows 10.1% revenue growth TTM and 7.8% latest-quarter growth, with gross margin at 86.2%, operating margin at 38.3%, and net margin at 35.5%, so the core earnings engine is intact. Valuation is not cheap — PE 27.9, forward PE 24.0, and PEG 2.28 — and beta 0.30 means the stock is usually less volatile than the market, but strong growth is already priced in, which can make even a small negative reaction around earnings feel outsized. Analyst consensus is still constructive, with 11 strong-positive, 19 positive, 6 neutral, 0 negative, and 1 strong-negative ratings, so there is no sign of a consensus downgrade driving the move.
Earnings preview
The next earnings date is 2026-08-03. The most recent quarter gives the benchmark: revenue rose 1.3% year over year to $3.3 billion, sales came in 3.32% above expectations, earnings missed by 1.25%, and non-GAAP profit of $4.73 per share was in line with consensus; full-year revenue guidance at a midpoint of $13.15 billion was 0.7% above analysts’ estimates. The market will be focused on whether CF franchise growth can keep offsetting mix pressure, how quickly CASGEVY and JOURNAVX are scaling, and whether margins stay near the current 86.2% gross, 38.3% operating, and 35.5% net levels. The facts do not give a longer history of post-earnings stock reactions, so I won’t infer a pattern that isn’t supplied here.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track VRTX with WhyIHold
Get a plain-English explanation the next time VERTEX PHARMACEUTICALS INC makes a big move — so you know whether it's benign or worth your attention.